Job Listings


Here are our current job openings. Please click on the job title for more information, and apply from that page if you are interested.

Use this form to perform another job search

The system cannot access your location for 1 of 2 reasons:
  1. Permission to access your location has been denied. Please reload the page and allow the browser to access your location information.
  2. Your location information has yet to be received. Please wait a moment then hit [Search] again.
Click column header to sort

Search Results Page 1 of 2

Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
CMC
ID
2021-1460
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Human Resources
ID
2021-1458
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.    Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Biostatistics, Programming & Data Management
ID
2021-1455
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.    Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Marketing
ID
2021-1454
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.    Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Marketing
ID
2021-1453
Job Locations US-FL-Orlando South | US-FL-Melbourne | US-FL-Stuart | US-FL-Lakeland
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Field Sales
ID
2021-1448
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.    Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Administrative Support
ID
2021-1446
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Human Resources
ID
2021-1444
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Clinical Development
ID
2021-1438
Job Locations US-CO-Denver
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Field Sales
ID
2021-1436
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Clinical Development
ID
2021-1431
Job Locations US-CA-Fresno
Improving quality-of-life through innovations in urology.   Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant’s lead product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.  GEMTESA® is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
Field Sales
ID
2021-1426
Job Locations US-IL-Chicago | US-MN-Minneapolis | US-MI-Ann Arbor | US-MI-Detroit | US-WI-Milwaukee
Improving quality-of-life through innovations in urology.   Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Field Sales
ID
2021-1425
Job Locations US-CA-Irvine | US-NC-Durham
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Biostatistics, Programming & Data Management
ID
2021-1423
Job Locations US-CA-Irvine
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Compliance
ID
2021-1421
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Overactive Bladder (OAB). Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as third line treatments for OAB symptoms in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Medical Affairs
ID
2021-1417
Job Locations US-CA-Irvine
Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success. We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve. Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant's lead product, GEMTESA (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant's second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
Information Technology
ID
2021-1411
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant’s lead product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.  GEMTESA® is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
Commercial Operations
ID
2021-1409
Job Locations US-CA-Irvine
Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant’s lead product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.  GEMTESA® is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
CMC
ID
2021-1403
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant’s lead product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.  GEMTESA® is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
CMC
ID
2021-1400